9 results
The primary objective is, to determine whether short term anti-IgE treatment with an anti-IgE monoclonal antibody (omalizumab) can limit intraplaque mast cell activation in atherosclerotic plaques.
To relate the reduction of inflammatory characteristics in skin and in peripheral blood to clinical efficacy in patients with CSU. Major focusses of this study are the (early) effects on basophils and other Fc*RI-bearing leukocytes before, during,…
- To evaluate the safety and efficacy of anti-IgE therapy with respect to:Clinical disease activity (DAS44), laboratory parameters and adverse events. - To evaluate whether disease activity correlates with immunological parameters, including…
The study objective is to evaluate the clinical outcome of percutaneous aortic valve implantation in consecutive *real world* patients with severe aortic valve stenosis intended to be treated with the Medtronic CoreValve System.
A clinical research study to find out if Xolair is safe and has beneficial effects in adolescents (12 years old and above) and adults with cystic fibrosis (CF) and ABPA. All patients entering the study will be taking oral corticosteroids (steroid…
The objective of this trial is to characterize annually the safety and durability data through 10 years in a subset of subjects randomized in the SURTAVI trial.
Objectives:Primary objective:To evaluate the efficacy of the 3 selected dose regimens of Padsevonil (PSL) administered concomitantly with up to 3 antiepileptic drugs (AEDs) compared with Placebo for treatment of observable focal-onset seizures in…
Objectives:Primary objectiveTo evaluate the long-term safety and tolerability of padsevonil (PSL) administered at individualized doses between 100 mg/day and 800 mg/day as adjunctive treatment for subjects with focal-onset seizures and drug-…
The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab.